

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

**SECTION 1: IDENTIFICATION**

Product name : Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

**Manufacturer or supplier's details**

Company : Intervet Australia Pty Limited (trading as MSD Animal Health)

Address : 91-105 Harpin Street  
Bendigo 3550, Victoria Australia

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Reproductive toxicity : Category 1A

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Kidney, inner ear)

**GHS label elements**

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.  
H373 May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapours.

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version 8.0	Revision Date: 03.12.2024	SDS Number: 772737-00021	Date of last issue: 06.07.2024 Date of first issue: 23.06.2016
----------------	------------------------------	-----------------------------	---

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Gentamicin	1403-66-3	$\geq 1$ - $< 10$
Posaconazole	171228-49-2	$< 1$
Mometasone	83919-23-7	$< 0.3$
3-Mercaptopropane-1,2-diol	96-27-5	$< 1$

**SECTION 4. FIRST AID MEASURES**

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: May damage the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

---

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

---

**SECTION 5. FIREFIGHTING MEASURES**

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Hazchem Code : •3Z

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate contain-

---

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

---

ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**SECTION 7. HANDLING AND STORAGE**

- |                             |   |  |
|-----------------------------|---|--|
| Technical measures          | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  |
| Local/Total ventilation     | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.  |
| Advice on safe handling     | : | Do not get on skin or clothing.<br>Do not breathe mist or vapours.<br>Do not swallow.<br>Avoid contact with eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment.                                    |
| Hygiene measures            | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.<br>When using do not eat, drink or smoke.<br>Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |
| Conditions for safe storage | : | Keep in properly labelled containers.<br>Store locked up.<br>Keep tightly closed.<br>Store in accordance with the particular national regulations.   |
| Materials to avoid          | : | Do not store with the following product types:<br>Strong oxidizing agents  |

---

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Components with workplace control parameters**

# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version 8.0      Revision Date: 03.12.2024      SDS Number: 772737-00021      Date of last issue: 06.07.2024  
Date of first issue: 23.06.2016

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Gentamicin	1403-66-3	TWA	0.1 mg/m <sup>3</sup> (OEB 2)	Internal
Further information: OTO				
Posaconazole	171228-49-2	TWA	300 µg/m <sup>3</sup> (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

## Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

## Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version 8.0	Revision Date: 03.12.2024	SDS Number: 772737-00021	Date of last issue: 06.07.2024 Date of first issue: 23.06.2016
----------------	------------------------------	-----------------------------	---

Skin and body protection : aerosols.  
: Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	: liquid
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies) Water solubility	: No data available
Partition coefficient: n-	: Not applicable

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

**SECTION 11. TOXICOLOGICAL INFORMATION**

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****Gentamicin:**

Acute oral toxicity : LD50 (Rat): 8,000 - 10,000 mg/kg  
LD50 (Mouse): 10,000 mg/kg

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): 67 - 96 mg/kg  
Application Route: Intravenous  
  
LD50 (Rat): 371 - 384 mg/kg  
Application Route: Intramuscular  
  
LDLo (Monkey): 30 mg/kg  
Application Route: Intravenous

**Posaconazole:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 3,000 mg/kg  
  
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

**Mometasone:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg  
  
Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: No mortality observed at this dose.  
  
LC50 (Mouse): > 3.2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
  
Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg  
Application Route: Subcutaneous  
Symptoms: Breathing difficulties

**3-Mercaptopropane-1,2-diol:**

Acute oral toxicity : LD50 (Rat): 648 mg/kg  
  
Acute dermal toxicity : LD50 (Rabbit): 673 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**Version  
8.0Revision Date:  
03.12.2024SDS Number:  
772737-00021Date of last issue: 06.07.2024  
Date of first issue: 23.06.2016

---

**Components:****Gentamicin:**

Species	: Rabbit
Result	: Mild skin irritation

**Posaconazole:**

Species	: Rabbit
Result	: No skin irritation

**Mometasone:**

Species	: Rabbit
Result	: No skin irritation

**3-Mercaptopropane-1,2-diol:**

Species	: Rabbit
Result	: Skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Gentamicin:**

Species	: Rabbit
Result	: Mild eye irritation

**Posaconazole:**

Species	: Rabbit
Result	: Mild eye irritation

**Mometasone:**

Species	: Rabbit
Result	: No eye irritation

**3-Mercaptopropane-1,2-diol:**

Species	: Rabbit
Result	: Irritation to eyes, reversing within 21 days

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

## Components:

### Gentamicin:

Remarks : No data available

### Posaconazole:

Test Type : Magnusson-Kligman-Test  
 Exposure routes : Skin contact  
 Species : Guinea pig  
 Result : negative

### Mometasone:

Test Type : Maximisation Test  
 Exposure routes : Dermal  
 Species : Guinea pig  
 Assessment : Does not cause skin sensitisation.  
 Result : negative  
 Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

### 3-Mercaptopropane-1,2-diol:

Test Type : Local lymph node assay (LLNA)  
 Exposure routes : Skin contact  
 Species : Mouse  
 Method : OECD Test Guideline 429  
 Result : positive

Assessment : Probability or evidence of low to moderate skin sensitisation rate in humans

## Chronic toxicity

### Germ cell mutagenicity

Not classified based on available information.

## Components:

### Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
 Result: negative  
 Test Type: Chromosome aberration test in vitro  
 Result: equivocal  
 Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
 Species: Mouse  
 Application Route: Intravenous injection  
 Result: negative

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version 8.0	Revision Date: 03.12.2024	SDS Number: 772737-00021	Date of last issue: 06.07.2024 Date of first issue: 23.06.2016
----------------	------------------------------	-----------------------------	---

**II****Posaconazole:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: Chromosomal aberration Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Intravenous Result: negative

**Mometasone:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: Chromosomal aberration Test system: Chinese hamster lung cells Result: negative  Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: positive  Test Type: Mouse Lymphoma Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative  Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative  Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

**3-Mercaptopropane-1,2-diol:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
-----------------------	--

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

---

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****Gentamicin:**

Carcinogenicity - Assessment	: No data available
------------------------------	---------------------

**Posaconazole:**

Species	: Rat
Application Route	: oral (feed)
Exposure time	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.

**Mometasone:**

Species	: Rat
Application Route	: Inhalation
Exposure time	: 2 Years
Dose	: 0.067 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Inhalation
Exposure time	: 19 Months
Dose	: 0.160 mg/kg body weight
Result	: negative

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**Version  
8.0Revision Date:  
03.12.2024SDS Number:  
772737-00021Date of last issue: 06.07.2024  
Date of first issue: 23.06.2016**Reproductive toxicity**

May damage the unborn child.

**Components:****Gentamicin:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Fertility: NOAEL: 20 mg/kg body weight Result: No significant adverse effects were reported
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rabbit Developmental Toxicity: NOAEL: 3.6 mg/kg body weight Result: No embryo-foetal toxicity  Test Type: Embryo-foetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 75 mg/kg body weight Result: Embryo-foetal toxicity  Test Type: Embryo-foetal development Species: Mouse Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed.  Test Type: Embryo-foetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: foetal mortality, No malformations were observed.
Reproductive toxicity - Assessment	: Positive evidence of adverse effects on development from human epidemiological studies.

**Posaconazole:**

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, male General Toxicity - Parent: NOAEL: 180 mg/kg body weight Symptoms: No effects on mating performance Result: negative  Test Type: Fertility/early embryonic development Species: Rat, female General Toxicity - Parent: NOAEL: 45 mg/kg body weight Symptoms: No effects on mating performance Result: negative
----------------------	---

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat, female Application Route: Oral Developmental Toxicity: LOAEL: 29 mg/kg body weight Result: Fetotoxicity, Malformations were observed.  Test Type: Embryo-foetal development Species: Rabbit, female Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.

**Mometasone:**

Effects on fertility	: Test Type: Fertility Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0.015 mg/kg body weight Symptoms: Reduced embryonic survival, Reduced foetal weight Result: No effects on fertility, Effect on reproduction capacity
Effects on foetal development	: Test Type: Embryo-foetal development Species: Mouse Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmental toxicity  Test Type: Embryo-foetal development Species: Rat Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight Result: Embryo-foetal toxicity  Test Type: Embryo-foetal development Species: Rabbit Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.  Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Effects on newborn  Test Type: Embryo-foetal development Species: Rabbit

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

	Application Route: Oral Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**3-Mercaptopropane-1,2-diol:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Method: OECD Test Guideline 416 Result: negative Remarks: Based on data from similar materials
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Method: OECD Test Guideline 414 Result: negative Remarks: Based on data from similar materials

**STOT - single exposure**

Not classified based on available information.

**Components:****Mometasone:**

Remarks	: Based on available data, the classification criteria are not met.
---------	---

**STOT - repeated exposure**

May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure if swallowed.

**Components:****Gentamicin:**

Target Organs	: Kidney, inner ear
Assessment	: Causes damage to organs through prolonged or repeated exposure.

**Posaconazole:**

Exposure routes	: Ingestion
Target Organs	: Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

---

**Mometasone:**

Exposure routes	: inhalation (dust/mist/fume)
Target Organs	: Immune system, Liver, Kidney, Skin
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Gentamicin:**

Species	: Dog
LOAEL	: 3 mg/kg
Application Route	: Intramuscular
Exposure time	: 12 Months
Target Organs	: Kidney
Symptoms	: Vomiting, Salivation

Species	: Monkey
LOAEL	: 50 mg/kg
Application Route	: Subcutaneous
Exposure time	: 3 Weeks
Target Organs	: Kidney, inner ear

Species	: Monkey
LOAEL	: 6 mg/kg
Application Route	: Intramuscular
Exposure time	: 3 Weeks
Target Organs	: Blood, Kidney, inner ear, Liver

Species	: Rat
NOAEL	: 5 mg/kg
LOAEL	: 10 mg/kg
Application Route	: Intramuscular
Exposure time	: 52 Weeks
Target Organs	: Kidney, Blood

Species	: Rat
NOAEL	: 12.5 mg/kg
LOAEL	: 50 mg/kg
Application Route	: Intramuscular
Exposure time	: 13 Weeks
Target Organs	: Kidney

**Posaconazole:**

Species	: Rat, female
LOAEL	: 5 mg/kg
Application Route	: Oral

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

---

Exposure time	: 6 Months
Target Organs	: Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species	: Dog
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 392 Days
Target Organs	: Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species	: Monkey
LOAEL	: 15 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Bone marrow, Adrenal gland, Lymph nodes, Blood

Species	: Dog
LOAEL	: 3 mg/kg
Application Route	: Oral
Exposure time	: 56 Weeks
Target Organs	: Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species	: Monkey
LOAEL	: 180 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Blood, Gastrointestinal tract, spleen

Species	: Monkey
LOAEL	: 8 mg/kg
Application Route	: Intravenous
Exposure time	: 1 Months
Target Organs	: Cardio-vascular system, Lungs, Adrenal gland, Blood

**Mometasone:**

Species	: Rat
NOAEL	: 0.005 mg/kg
LOAEL	: 0.3 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Dog
LOAEL	: 0.5 mg/kg
Application Route	: Oral
Exposure time	: 30 d
Target Organs	: Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	: Rat
---------	-------

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

NOAEL	: 0.00013 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 90 d
Target Organs	: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species	: Dog
NOAEL	: 0.0005 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 90 d
Target Organs	: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

**3-Mercaptopropane-1,2-diol:**

Species	: Rat
LOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 55 Days
Method	: OECD Test Guideline 422
Remarks	: Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Components:****Mometasone:**

Not applicable

**Experience with human exposure****Components:****Gentamicin:**

Ingestion	: Target Organs: Kidney Target Organs: inner ear Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness
-----------	---

**Posaconazole:**

Ingestion	: Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance
-----------	--

**Mometasone:**

Inhalation	: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	: Symptoms: Dermatitis, Itching

# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

## Further information

### Components:

#### Mometasone:

||Remarks : Dermal absorption possible

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### Gentamicin:

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 86 mg/l Exposure time: 48 h Method: OECD Test Guideline 202  LC50 (Americamysis): 30 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l Exposure time: 72 h Method: OECD Test Guideline 201  NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l Exposure time: 72 h Method: OECD Test Guideline 201  EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l Exposure time: 72 h Method: OECD Test Guideline 201  NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50: 288.7 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

##### Posaconazole:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
------------------	---	--

# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0.276 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l Exposure time: 72 h Method: OECD Test Guideline 201  NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.244 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	: EC50 (Natural microorganism): > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

## Mometasone:

Toxicity to fish	: LC50 (Menidia beryllina (Silverside)): 0.11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility  LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility  EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l

# Mometasone / Posaconazole / Gentamicin / Polymyxin B Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

	Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.34 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
Toxicity to microorganisms	: EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
	NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility

## 3-Mercaptopropane-1,2-diol:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 10 - 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): > 10 - 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	: ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 10 - 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
	EC10 (Raphidocelis subcapitata (freshwater green alga)): > 1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC10 (activated sludge): > 1 mg/l

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

---

Exposure time: 3 h  
Method: OECD Test Guideline 209  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Gentamicin:**

Biodegradability : Result: rapidly degradable  
Biodegradation: 100 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

**Posaconazole:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 h  
Method: OECD Test Guideline 314

Stability in water : Degradation half life (DT50): > 30 d  
Method: OECD Test Guideline 111

**Mometasone:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)  
Method: OECD Test Guideline 111

**3-Mercaptopropane-1,2-diol:**

Biodegradability : Result: Readily biodegradable.  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Gentamicin:**

Partition coefficient: n-octanol/water : log Pow: < -2

**Posaconazole:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 20  
Method: OECD Test Guideline 305

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

---

Partition coefficient: n-octanol/water : log Pow: 4.15

**Mometasone:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 107.1  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

**3-Mercaptopropane-1,2-diol:**

Partition coefficient: n-octanol/water : log Pow: -0.84  
Method: OECD Test Guideline 117

**Mobility in soil****Components:****Posaconazole:**

Distribution among environmental compartments : log Koc: 5.52

**Mometasone:**

Distribution among environmental compartments : log Koc: 4.02

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Gentamicin, Mometasone)

Class : 9  
Packing group : III

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

---

Labels : 9  
Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082  
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(Gentamicin, Mometasone)  
Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 964  
Packing instruction (passenger aircraft) : 964  
Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Gentamicin, Mometasone)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**National Regulations****ADG**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(Gentamicin, Mometasone)  
Class : 9  
Packing group : III  
Labels : 9  
Hazchem Code : •3Z  
Environmentally hazardous : yes

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

**SECTION 15. REGULATORY INFORMATION**

**Safety, health and environmental regulations/legislation specific for the substance or mixture**

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

Therapeutic Goods (Poisons Standard) Instrument : Schedule 5 (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

**The components of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**SECTION 16: ANY OTHER RELEVANT INFORMATION****Further information**

Revision Date : 03.12.2024  
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect

**Mometasone / Posaconazole / Gentamicin /  
Polymyxin B Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
8.0	03.12.2024	772737-00021	Date of first issue: 23.06.2016

---

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN